OncoMatch/Clinical Trials/NCT05159245
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Is NCT05159245 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for advanced cancer.
Treatment: Alectinib · Cobimetinib · Vismodegib · Trastuzumab+Pertuzumab · Entrectinib · Atezolizumab · Vemurafenib · Regorafenib · Apalutamide · Abemaciclib · Tepotinib · Dabrafenib · Trametinib · Dabrafenib+Trametinib · Pemigatinib — This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Disease stage
Metastatic disease required
histologically-confirmed locally advanced or metastatic cancer; objectively evaluable or measurable disease (by physical or radiographic examination, according to RECIST v1.1, Lugano, IWG and ELN-AML, IMWG, RANO, GCIG, iRESIST or PCWG3)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard anti-cancer treatment
no longer benefitting from standard anti-cancer treatment or for whom no such treatment is available or indicated
Cannot have received: colony-stimulating factors (G-CSF, GM-CSF, recombinant EPO)
Received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 14 days prior to the first dose of study intervention
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9/l; Hemoglobin > 8.0 mmol/l, without blood transfusion within 7 days; Platelets > 75 x 10^9/l (not applicable for hematological patients)
Kidney function
Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 40 mL/min/1.73 m2
Liver function
Total bilirubin < 1.5 x ULN; AST and ALT < 3 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases)
Cardiac function
Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure are not eligible. Patients with known left ventricular ejection fraction (LVEF) < 45% are not eligible.
Patients must have acceptable organ function as defined below... see details in criteria.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify